At standard dosing, a 70mg vial lasts approximately 30 days
The SMA focuses on providing enhanced equity-based income and capital appreciation in a tax-aware manner
Administered intramuscularly or intravenously, it helps support nerve health and energy metabolism
Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy
If any side effects persist, consult a healthcare professional promptly
Treatment duration depends on your sleep quality baseline, underlying sleep issues, response to therapy, whether youre addressing acute sleep disruption or chronic sleep quality challenges, and your physicians assessment
